Article Information
History
- September 15, 2020.
Article Versions
- You are currently viewing Version 1 of this article (September 15, 2020 - 08:18).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Leticia R. Cruz1,*,
- Idania Baladrón2,*,
- Aliusha Rittoles1,
- Pablo A. Díaz2,
- Carmen Valenzuela3,
- Raúl Santana1,
- Maria M. Vázquez2,
- Ariadna García1,
- Deyli Chacón1,
- Delvin Thompson1,
- Gustavo Perera1,
- Ariel González4,
- Rafael Reyes5,
- Loida Torres4,
- Jesus Pérez1,
- Dania M. Vázquez2,
- Gilda Lemus2,
- Mauro Rosales2,6,
- Ailyn C. Ramón2,
- George V. Perez2,
- Gerardo Guillén2,
- Verena Muzio2,
- Yasser Perera2,7,
- Silvio E. Perea2,†,
- for the ATENEA-Co-300 group♣
- 1Central Hospital “Luis Diaz Soto”, Havana 19130, Cuba
- 2Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba
- 3Center for Molecular Immunology, Havana 11600, Cuba
- 4International Center of Health “La Pradera”, Havana 11600, Cuba
- 5National Institute of Oncology and Radiobiology, Havana 10400, Cuba
- 6Faculty of Biology, University of Havana, Havana 10400, Cuba
- 7China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Yongzhou Zhong Gu Biotechnology Co., Ltd, Yangjiaqiao Street, Lengshuitan District, Yongzhou City, Hunan 425000, China
- ↵†
Corresponding Author:
Silvio E. Perea, PhD, Prof (silvio.perea{at}cigb.edu.cu) Head of the Molecular Oncology Group, Biomedical Research Area, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba
↵* These authors contributed equally to this work
Posted September 15, 2020.
Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in Covid-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial
